MARKET

CELC

CELC

Celcuity Inc
NASDAQ
10.53
+0.44
+4.36%
After Hours: 10.53 0 0.00% 16:05 03/19 EDT
OPEN
10.12
PREV CLOSE
10.09
HIGH
10.85
LOW
10.02
VOLUME
124.38K
TURNOVER
--
52 WEEK HIGH
22.19
52 WEEK LOW
8.53
MARKET CAP
390.97M
P/E (TTM)
-4.0390
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CELC last week (0310-0314)?
Weekly Report · 2d ago
Tracking Baker Brothers Portfolio - Q4 2024 Update
Seeking Alpha · 6d ago
Weekly Report: what happened at CELC last week (0303-0307)?
Weekly Report · 03/10 11:38
Weekly Report: what happened at CELC last week (0224-0228)?
Weekly Report · 03/03 11:37
Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences
Barchart · 02/25 06:05
Weekly Report: what happened at CELC last week (0217-0221)?
Weekly Report · 02/24 11:37
Celcuity's High-Stakes Oncology Bet Is Underappreciated
Seeking Alpha · 02/19 23:24
Weekly Report: what happened at CELC last week (0210-0214)?
Weekly Report · 02/17 11:34
More
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.

Webull offers Celcuity Inc stock information, including NASDAQ: CELC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CELC stock methods without spending real money on the virtual paper trading platform.